BRANFORD, Conn. / Nov 01, 2023 / Business Wire / Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), The Protein Sequencing CompanyTM, today announced that it will be participating in two upcoming investor conferences:
About the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
Quantum-Si management will attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum, taking place at the Westin NY Grand Central on Thursday, November 16, 2023.
Jeff Hawkins, Chief Executive Officer of Quantum-Si, will participate in a fireside chat on Thursday, November 16, at 4:30 – 4:55 p.m. Eastern Time.
About the 6th Annual Evercore ISI HealthCONx Conference
Quantum-Si management will attend the 6th Annual Evercore ISI HealthCONx Conference, taking place at the Kimpton Epic Hotel in Miami, Florida on November 28-30, 2023.
Jeff Hawkins will participate in a fireside chat on Wednesday, November 29, at 7:55 – 8:15 a.m. Eastern Time.
Where to View
A live and archived webcast of both events will be available in the “Investors” section of the Quantum-Si website under Events & Presentations.
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com.
| Last Trade: | US$1.32 |
| Daily Change: | 0.01 0.76 |
| Daily Volume: | 5,279,765 |
| Market Cap: | US$205.870M |
December 20, 2024 December 04, 2024 November 21, 2024 November 20, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
